AKANDA CORP. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.525 USD | +10.75% |
|
+6.37% | -85.51% |
| 28/05 | Top Premarket Decliners | MT |
| 24/05 | Top Premarket Gainers | MT |
| Sales 2022 | 2.62 218.8 | Sales 2023 | 2.16 180.41 | Capitalization | 17.73L 15Cr |
|---|---|---|---|---|---|
| Net income 2022 | -1.1Cr -92Cr | Net income 2023 | -3.2Cr -267.27Cr | EV / Sales 2022 | 18,45,573 x |
| Net Debt 2022 | 3.41 284.58 | Net Debt 2023 | 3.92 327.07 | EV / Sales 2023 | 8,20,820 x |
| P/E ratio 2022 |
-0.38
x | P/E ratio 2023 |
-0.06
x | Employees | 46 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 97.82% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +10.75% | ||
| 1 week | +6.37% | ||
| Current month | -1.81% | ||
| 1 month | -31.37% | ||
| 3 months | -69.46% | ||
| 6 months | -84.66% | ||
| Current year | -85.51% |
1 week
2.16
2.88
1 month
2.125.66
Current year
2.1228.40
1 year
2.1242.00
3 years
2.1212 400.00
5 years
2.1212 400.00
10 years
2.1212 400.00
| Managers | Title | Age | Since |
|---|---|---|---|
Katharyn Field
CEO | Chief Executive Officer | 41 | 23/22/23 |
Charn Deol
DFI | Director of Finance/CFO | 56 | 11/12 |
Matt Chesler
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jay Dhaliwal
BRD | Director/Board Member | 35 | 23/22/23 |
Katharyn Field
CEO | Chief Executive Officer | 41 | 23/22/23 |
David Jenkins
BRD | Director/Board Member | 43 | 13/23/13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 2.55 | +11.84% | 1 038 120 |
| 20/24/20 | 2.28 | +2.24% | 925,852 |
| 18/24/18 | 2.23 | -1.76% | 151,206 |
| 17/24/17 | 2.27 | -5.42% | 92,514 |
| 14/24/14 | 2.4 | -4.76% | 248,821 |
Delayed Quote Nasdaq, June 21, 2024 at 07:42 pm IST
More quotes
Akanda Corp. is an international medical cannabis and wellness platform company. The Companyâs portfolio includes Canmart Ltd. (CanMart), a United Kingdom-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the United Kingdom. Canmart is a licensed importer and distributor of CBD Extraction for Medicinal Purposes (CBPMs) in the United Kingdom. CanMart holds a controlled drug license issued by the Home Office to possess and supply CBPMs in the United Kingdom. The Company's seed-to-patient supply chain also includes partnerships Cellen Life Sciences' Leva Clinic, a fully digital pain clinic in the United Kingdom. The Company also develops a Canadian farming property in British Columbia, including farming land and related operations and licenses. The Company also focuses on developing tetrahydrocannabinol (THC) and cannabinoid (CBD) facilities at this site.
| 1st Jan change | Capi. | |
|---|---|---|
| -85.51% | 43.7L | |
| +6.17% | 22Cr | |
| -9.28% | 19Cr | |
| +21.80% | 16Cr | |
| +28.26% | 12Cr | |
| -42.86% | 9.66Cr | |
| -57.07% | 9.03Cr | |
| -7.69% | 8.02Cr |
- Stock Market
- Equities
- AKAN Stock
